Arcutis Biotherapeutics, Inc. (ARQT) vs its competitors

Arcutis Biotherapeutics, Inc. against biotechnology

Arcutis Biotherapeutics, Inc. is the 61st largest of 361 graded companies. Showing 5 of them, including ARQT itself. 235 more are in this industry but have no grade yet, so they are left out rather than shown blank.

Company	Grade	Market value	Revenue	Profit margin	Free cash flow	Price to earnings
vTv Therapeutics Inc.VTVT	D-	—	$36.8M	-12.9%	-$25.3M	—
Crinetics Pharmaceuticals, Inc.CRNX	D-	—	$42.2M	-1,189.9%	-$425.2M	—
Barinthus Biotherapeutics plcBRNS	D-	—	$0.00	—	-$26.4M	—
Vertex Pharmaceuticals Inc. / MAVRTX	B+	$133.5B	$12.6B	35.0%	$3.8B	30.68
Arcutis Biotherapeutics, Inc.ARQT	A	$3.4B	$464M	6.1%	$39.2M	127.33

356 more biotechnology companies

Graded on the same five checks, from their own SEC filings.

A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.

Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Arcutis Biotherapeutics, Inc. on the overview — nothing here comes from a data vendor’s own ratios.

Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.